Eyal C. Attar Sells 15,968 Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE) SVP Eyal C. Attar sold 15,968 shares of the company’s stock in a transaction that occurred on Thursday, September 16th. The shares were sold at an average price of $4.68, for a total value of $74,730.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

APRE traded down $0.21 during trading hours on Monday, hitting $4.85. The company’s stock had a trading volume of 18,458,790 shares, compared to its average volume of 2,064,534. Aprea Therapeutics, Inc. has a fifty-two week low of $3.17 and a fifty-two week high of $30.99. The firm has a market capitalization of $102.76 million and a PE ratio of -2.46. The company has a 50-day simple moving average of $4.40 and a 200 day simple moving average of $4.70.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Thursday, August 12th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Equities analysts expect that Aprea Therapeutics, Inc. will post -1.77 earnings per share for the current year.

Several brokerages have issued reports on APRE. Berenberg Bank cut Aprea Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Monday, August 16th. HC Wainwright dropped their price target on Aprea Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a research report on Monday, August 16th. Morgan Stanley cut Aprea Therapeutics from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $5.00 to $3.00 in a research report on Thursday, August 12th. Royal Bank of Canada dropped their price target on Aprea Therapeutics from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Friday, August 13th. Finally, JPMorgan Chase & Co. cut Aprea Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, August 20th. Two analysts have rated the stock with a sell rating and five have given a hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $4.15.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Aprea Therapeutics during the 1st quarter valued at $42,000. JPMorgan Chase & Co. boosted its stake in Aprea Therapeutics by 380.3% during the 1st quarter. JPMorgan Chase & Co. now owns 16,550 shares of the company’s stock valued at $85,000 after purchasing an additional 13,104 shares in the last quarter. Geode Capital Management LLC boosted its stake in Aprea Therapeutics by 9.1% during the 1st quarter. Geode Capital Management LLC now owns 161,147 shares of the company’s stock valued at $821,000 after purchasing an additional 13,457 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Aprea Therapeutics by 57.5% during the 1st quarter. Bank of New York Mellon Corp now owns 47,783 shares of the company’s stock valued at $244,000 after purchasing an additional 17,447 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in Aprea Therapeutics by 2,725.9% during the 1st quarter. SG Americas Securities LLC now owns 655,888 shares of the company’s stock valued at $3,345,000 after purchasing an additional 632,678 shares in the last quarter. Hedge funds and other institutional investors own 30.73% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers.

Read More: What are benefits of a growth and income fund?

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.